VIVUS Press Releases

Date Title Links
Toggle Summary VIVUS Reports Data Supporting the Cardiovascular Safety of Qsymia®
-Retrospective analysis presented at the 34 th International Conference on Pharmacoepidemiology & Therapeutic Risk Management - CAMPBELL, Calif. , Aug. 27, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, has reported encouraging data from a
View HTML
Toggle Summary VIVUS Announces Positive Results from a Phase 1 Clinical Trial of VI-0106
-Favorable pharmacokinetic results add to body of data supporting continued development in the treatment of pulmonary arterial hypertension- CAMPBELL, Calif. , July 10, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, today announced positive
View HTML
Toggle Summary VIVUS Executes on its Strategic Vision with the Closing of its Acquisition of PANCREAZE® and Previously Announced Financing Transaction
CAMPBELL, Calif. , June 11, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, today announced that it has met the closing conditions, including Hart-Scott-Rodino review, related to the Company’s previously announced acquisition of U.S.
View HTML
Toggle Summary VIVUS Expands its Commercial Product Portfolio with the Acquisition of PANCREAZE®
Attains key milestone under strategic focus on building a broad portfolio of cash flow-generating products   CAMPBELL, CA., May 1, 2018 – VIVUS, Inc. (N asdaq : VVUS; the “Company”), a biopharmaceutical company, today announced that it has entered into a definitive agreement to acquire all product
View HTML
Toggle Summary VIVUS Announces Change in Leadership
Board Member Thomas B. King appointed interim CEO; Seth Fischer steps down as CEO effective December 31, 2017 CAMPBELL, CA -- (Marketwired) -- 12/26/17 -- VIVUS, Inc. (NASDAQ: VVUS) today announced that it has reached agreement with Seth H. Z. Fischer pursuant to which he will step down as chief
View HTML
Toggle Summary VIVUS Completes Tacrolimus Pre-IND Meeting With FDA
Company on track to initiate clinical trials in 2018
View HTML
Toggle Summary VIVUS Announces Tacrolimus Receives Orphan Drug Designation in the European Union for the Treatment of Pulmonary Arterial Hypertension
CAMPBELL, CA -- (Marketwired) -- 09/06/17 -- VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today announced that the European
View HTML
Toggle Summary VIVUS and Alvogen Announce Marketing Agreement for Qsymia(R) in the Republic of Korea
CAMPBELL, CA , and SAN GWANN, MALTA -- (Marketwired) -- 09/05/17 -- VIVUS, Inc. (NASDAQ: VVUS) and Alvogen Malta Operations (ROW) Ltd , today announced an agreement under which Alvogen will market Qsymia ® (phentermine and topiramate extended-release) in the Republic of Korea for the treatment of
View HTML
Toggle Summary VIVUS Announces Settlement with Dr. Reddy's Laboratories on Qsymia(R) Patent Litigation
CAMPBELL, CA -- (Marketwired) -- 08/30/17 -- VIVUS, Inc. (NASDAQ: VVUS) announced today that it has entered into a settlement agreement with Dr. Reddy's Laboratories, S.A. and Dr. Reddy's Laboratories, Inc. (Dr. Reddy's) resolving patent litigation related to Qsymia® (phentermine and topiramate
View HTML
Toggle Summary VIVUS Announces Settlement with Actavis on Qsymia(R) Patent Litigation
CAMPBELL, CA -- (Marketwired) -- 07/05/17 -- VIVUS, Inc. (NASDAQ: VVUS) announced today that it has entered into a settlement agreement with Actavis Laboratories FL (Actavis) resolving patent litigation related to Qsymia® (phentermine and topiramate extended-release) capsules CIV.
View HTML